Lavipharm announces the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N and Lonalgal, for the markets of Greece and Cyprus with the intention to commercialize them internationally.

According to the announcment, historical total sales of both pharmaceutical products amounted to approximately €8 million annually (Wholesale Prices). The transaction will be financed by the company’s own funds.

The products are commercially available in the Greek market and are expected to be marketed by Lavipharm during the first quarter of 2024 upon completion of the relevant product marketing authorizations’ transfer.